Physician profile
Amanda N Wilson
NPI 1467826776
$13,084.40
in general payments reported to CMS, 2019-2025
54 companies · $2,677 in 2025
The $2,677 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,005 · 2022: $1,776 · 2023: $2,729 · 2024: $2,898 · 2025: $2,677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,237 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,237.35 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,598.18 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,343.72 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $1,235.62 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Glaxosmithkline, LLC. | $1,034.22 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $946.97 | 2021-2025 | |
| Esperion Therapeutics, INC. | $802.84 | 2021-2022 | |
| Exact Sciences Corporation | $549.25 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $510.50 | 2021-2025 | Xifaxan |
| Astellas Pharma US INC | $473.07 | 2022-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $465.12 | 2021-2025 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Pfizer INC. | $396.08 | 2021-2025 | |
| Alk-Abello, INC | $324.66 | 2024-2025 | Ragwitek, Odactra, Grastek |
| Axsome Therapeutics, INC. | $282.01 | 2022-2025 | Auvelity, Symbravo |
| Amgen INC. | $261.20 | 2021-2025 | Otezla, Repatha, Evenity |
| Daiichi Sankyo INC. | $240.47 | 2022-2024 | Injectafer |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.